vs
Immunovant, Inc.（IMVT）与维珍银河（SPCE）财务数据对比。点击上方公司名可切换其他公司
Immunovant, Inc.的季度营收约是维珍银河的2.0倍（$8.4M vs $4.2M），Immunovant, Inc.净利率更高（-899.0% vs -2222.2%，领先1323.1%），Immunovant, Inc.同比增速更快（140.7% vs 125.5%），Immunovant, Inc.自由现金流更多（$-59.8M vs $-113.5M）
Immunovant是一家临床阶段生物制药企业，专注于开发用于治疗严重、罕见自身免疫性疾病及炎症性疾病的新型单克隆抗体疗法，其核心在研候选产品覆盖多种自身免疫适应症，面向全球医疗市场布局研发管线。
维珍银河控股是英美合资的太空飞行公司，由理查德·布兰森创立，维珍集团通过维珍投资有限公司持有该公司11.9%的股份，公司核心业务围绕商业载人太空旅行展开，是全球商业太空探索领域的先行者。
IMVT vs SPCE — 直观对比
营收规模更大
IMVT
是对方的2.0倍
$4.2M
营收增速更快
IMVT
高出15.2%
125.5%
净利率更高
IMVT
高出1323.1%
-2222.2%
自由现金流更多
IMVT
多$53.7M
$-113.5M
损益表 — Q4 FY2024 vs Q2 FY2024
| 指标 | | |
|---|---|---|
| 营收 | $8.4M | $4.2M |
| 净利润 | $-75.3M | $-93.8M |
| 毛利率 | — | -546.6% |
| 营业利润率 | -896.2% | -2412.1% |
| 净利率 | -899.0% | -2222.2% |
| 营收同比 | 140.7% | 125.5% |
| 净利润同比 | -26.7% | 30.2% |
| 每股收益（稀释后） | $-0.50 | $-4.36 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IMVTSPCE
| Q2 24 | — | $4.2M | ||
| Q1 24 | $8.4M | $2.0M | ||
| Q4 23 | $8.9M | $2.8M | ||
| Q3 23 | $3.6M | $1.7M | ||
| Q2 23 | $4.1M | $1.9M | ||
| Q1 23 | $3.5M | — | ||
| Q4 22 | $2.9M | $869.0K | ||
| Q3 22 | $1.2M | $767.0K |
净利润IMVTSPCE
| Q2 24 | — | $-93.8M | ||
| Q1 24 | $-75.3M | $-102.0M | ||
| Q4 23 | $-51.4M | $-104.0M | ||
| Q3 23 | $-58.7M | $-104.6M | ||
| Q2 23 | $-73.9M | $-134.4M | ||
| Q1 23 | $-59.4M | — | ||
| Q4 22 | $-63.2M | $-150.8M | ||
| Q3 22 | $-47.9M | $-145.6M |
毛利率IMVTSPCE
| Q2 24 | — | -546.6% | ||
| Q1 24 | — | -1038.1% | ||
| Q4 23 | — | -766.4% | ||
| Q3 23 | — | -1384.3% | ||
| Q2 23 | — | 87.5% | ||
| Q1 23 | — | — | ||
| Q4 22 | — | -34.5% | ||
| Q3 22 | — | 23.1% |
营业利润率IMVTSPCE
| Q2 24 | — | -2412.1% | ||
| Q1 24 | -896.2% | -5599.9% | ||
| Q4 23 | -576.8% | -4067.8% | ||
| Q3 23 | -1629.6% | -6613.0% | ||
| Q2 23 | -1819.1% | -7459.4% | ||
| Q1 23 | -1736.3% | — | ||
| Q4 22 | -2134.5% | -17642.2% | ||
| Q3 22 | -4130.6% | -18978.0% |
净利率IMVTSPCE
| Q2 24 | — | -2222.2% | ||
| Q1 24 | -899.0% | -5139.1% | ||
| Q4 23 | -575.6% | -3701.8% | ||
| Q3 23 | -1642.3% | -6053.5% | ||
| Q2 23 | -1818.9% | -7181.4% | ||
| Q1 23 | -1707.8% | — | ||
| Q4 22 | -2147.7% | -17355.6% | ||
| Q3 22 | -4153.2% | -18977.1% |
每股收益（稀释后）IMVTSPCE
| Q2 24 | — | $-4.36 | ||
| Q1 24 | $-0.50 | $-5.10 | ||
| Q4 23 | $-0.36 | $-14.49 | ||
| Q3 23 | $-0.45 | $-5.57 | ||
| Q2 23 | $-0.57 | $-9.16 | ||
| Q1 23 | $-0.46 | — | ||
| Q4 22 | $-0.49 | $-0.55 | ||
| Q3 22 | $-0.41 | $-0.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $635.4M | $775.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $617.8M | $394.8M |
| 总资产 | $666.4M | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IMVTSPCE
| Q2 24 | — | $775.7M | ||
| Q1 24 | $635.4M | $765.2M | ||
| Q4 23 | $690.9M | $874.0M | ||
| Q3 23 | $269.9M | $997.1M | ||
| Q2 23 | $330.0M | $940.2M | ||
| Q1 23 | $376.5M | — | ||
| Q4 22 | $432.6M | $909.0M | ||
| Q3 22 | $405.8M | $1.0B |
股东权益IMVTSPCE
| Q2 24 | — | $394.8M | ||
| Q1 24 | $617.8M | $417.6M | ||
| Q4 23 | $679.3M | $505.5M | ||
| Q3 23 | $251.8M | $599.4M | ||
| Q2 23 | $299.9M | $484.5M | ||
| Q1 23 | $362.5M | — | ||
| Q4 22 | $414.7M | $480.2M | ||
| Q3 22 | $395.7M | $613.5M |
总资产IMVTSPCE
| Q2 24 | — | $1.1B | ||
| Q1 24 | $666.4M | $1.1B | ||
| Q4 23 | $711.4M | $1.2B | ||
| Q3 23 | $292.1M | $1.3B | ||
| Q2 23 | $351.2M | $1.1B | ||
| Q1 23 | $405.8M | — | ||
| Q4 22 | $456.2M | $1.1B | ||
| Q3 22 | $428.1M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-59.7M | $-79.1M |
| 自由现金流经营现金流 - 资本支出 | $-59.8M | $-113.5M |
| 自由现金流率自由现金流/营收 | -714.4% | -2690.7% |
| 资本支出强度资本支出/营收 | 1.8% | 815.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-214.6M | $-458.3M |
8季度趋势，按日历期对齐
经营现金流IMVTSPCE
| Q2 24 | — | $-79.1M | ||
| Q1 24 | $-59.7M | $-113.2M | ||
| Q4 23 | $-47.1M | $-95.3M | ||
| Q3 23 | $-60.1M | $-91.5M | ||
| Q2 23 | $-47.4M | $-125.3M | ||
| Q1 23 | $-55.8M | — | ||
| Q4 22 | $-46.4M | $-131.2M | ||
| Q3 22 | $-20.2M | $-96.0M |
自由现金流IMVTSPCE
| Q2 24 | — | $-113.5M | ||
| Q1 24 | $-59.8M | $-126.3M | ||
| Q4 23 | $-47.2M | $-113.7M | ||
| Q3 23 | $-60.1M | $-104.8M | ||
| Q2 23 | $-47.4M | $-135.2M | ||
| Q1 23 | $-55.8M | — | ||
| Q4 22 | $-46.5M | $-135.4M | ||
| Q3 22 | $-20.2M | $-102.1M |
自由现金流率IMVTSPCE
| Q2 24 | — | -2690.7% | ||
| Q1 24 | -714.4% | -6362.8% | ||
| Q4 23 | -528.7% | -4046.9% | ||
| Q3 23 | -1682.4% | -6066.1% | ||
| Q2 23 | -1166.4% | -7224.3% | ||
| Q1 23 | -1604.0% | — | ||
| Q4 22 | -1579.2% | -15584.0% | ||
| Q3 22 | -1751.9% | -13305.2% |
资本支出强度IMVTSPCE
| Q2 24 | — | 815.5% | ||
| Q1 24 | 1.8% | 658.5% | ||
| Q4 23 | 1.5% | 653.9% | ||
| Q3 23 | 1.0% | 771.1% | ||
| Q2 23 | 1.1% | 526.4% | ||
| Q1 23 | 0.7% | — | ||
| Q4 22 | 3.3% | 481.4% | ||
| Q3 22 | 2.7% | 784.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
